EGFR and non-small cell lung carcinoma: A retrospective cohort analysis (N = 285) on OS and characterization of NSCLC patients showed that EGFR-mutant patients had a better OS than nonmutated patients (20.0 vs. 11.0 months, respectively; P value: 0.007) [57].